29.66
0.06 (0.20%)
| Penutupan Terdahulu | 29.60 |
| Buka | 29.71 |
| Jumlah Dagangan | 2,791,119 |
| Purata Dagangan (3B) | 2,304,218 |
| Modal Pasaran | 4,897,384,960 |
| Harga / Pendapatan (P/E TTM) | 14.76 |
| Harga / Pendapatan (P/E Ke hadapan) | 21.55 |
| Harga / Jualan (P/S) | 3.74 |
| Harga / Buku (P/B) | 3.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Oct 2025 |
| Margin Keuntungan | 23.30% |
| Margin Operasi (TTM) | 4.50% |
| EPS Cair (TTM) | 2.10 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -12.50% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -39.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.90% |
| Nisbah Semasa (MRQ) | 3.33 |
| Aliran Tunai Operasi (OCF TTM) | 516.83 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 429.53 M |
| Pulangan Atas Aset (ROA TTM) | 11.62% |
| Pulangan Atas Ekuiti (ROE TTM) | 25.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Menaik | |
| Stok | Alkermes plc | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 2.75 |
|
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.49% |
| % Dimiliki oleh Institusi | 107.53% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 55.00 (Truist Securities, 85.44%) | Beli |
| Median | 45.00 (51.72%) | |
| Rendah | 37.00 (Wells Fargo, 24.75%) | Beli |
| Purata | 45.20 (52.39%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 30.50 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Truist Securities | 17 Nov 2025 | 55.00 (85.43%) | Beli | 29.33 |
| 12 Nov 2025 | 50.00 (68.58%) | Beli | 31.41 | |
| Deutsche Bank | 13 Nov 2025 | 45.00 (51.72%) | Beli | 31.01 |
| Wells Fargo | 13 Nov 2025 | 37.00 (24.75%) | Beli | 31.01 |
| 29 Oct 2025 | 42.00 (41.60%) | Beli | 31.45 | |
| Needham | 29 Oct 2025 | 44.00 (48.35%) | Beli | 31.45 |
| Mizuho | 27 Oct 2025 | 45.00 (51.72%) | Beli | 29.72 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Jan 2026 | Pengumuman | Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1 |
| 30 Dec 2025 | Pengumuman | Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 25 Nov 2025 | Pengumuman | Alkermes to Participate in Two Upcoming Investor Conferences |
| 19 Nov 2025 | Pengumuman | Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc |
| 14 Nov 2025 | Pengumuman | Alkermes Response to Avadel Announcement |
| 12 Nov 2025 | Pengumuman | Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2 |
| 06 Nov 2025 | Pengumuman | Alkermes to Participate in Two Upcoming Investor Conferences |
| 05 Nov 2025 | Pengumuman | FORM 8.1(a) & (b) (Opening Position Disclosure) |
| 28 Oct 2025 | Pengumuman | Alkermes plc Reports Third Quarter 2025 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |